Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 116

1.

Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome.

Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E.

Neurobiol Dis. 2020 Jan 24;137:104772. doi: 10.1016/j.nbd.2020.104772. [Epub ahead of print]

2.

Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression.

Tramutola A, Falcucci S, Brocco U, Triani F, Lanzillotta C, Donati M, Panetta C, Luzi F, Iavarone F, Vincenzoni F, Castagnola M, Perluigi M, Di Domenico F, Marco F.

Cancers (Basel). 2020 Jan 1;12(1). pii: E110. doi: 10.3390/cancers12010110.

3.

Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.

Lanzillotta C, Di Domenico F, Perluigi M, Butterfield DA.

CNS Drugs. 2019 Oct;33(10):957-969. doi: 10.1007/s40263-019-00658-8.

PMID:
31410665
4.

Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome.

Di Domenico F, Tramutola A, Barone E, Lanzillotta C, Defever O, Arena A, Zuliani I, Foppoli C, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA, Perluigi M.

Redox Biol. 2019 May;23:101162. doi: 10.1016/j.redox.2019.101162. Epub 2019 Mar 9.

5.

Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity.

Cimini FA, Arena A, Barchetta I, Tramutola A, Ceccarelli V, Lanzillotta C, Fontana M, Bertoccini L, Leonetti F, Capoccia D, Silecchia G, Di Cristofano C, Chiappetta C, Di Domenico F, Baroni MG, Perluigi M, Cavallo MG, Barone E.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1490-1501. doi: 10.1016/j.bbadis.2019.02.021. Epub 2019 Feb 28.

PMID:
30826467
6.

Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease.

Sharma N, Tramutola A, Lanzillotta C, Arena A, Blarzino C, Cassano T, Butterfield DA, Di Domenico F, Perluigi M, Barone E.

Neurobiol Dis. 2019 May;125:176-189. doi: 10.1016/j.nbd.2019.02.003. Epub 2019 Feb 6.

PMID:
30738142
7.

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome.

Tramutola A, Lanzillotta C, Barone E, Arena A, Zuliani I, Mosca L, Blarzino C, Butterfield DA, Perluigi M, Di Domenico F.

Transl Neurodegener. 2018 Nov 6;7:28. doi: 10.1186/s40035-018-0133-9. eCollection 2018.

8.

Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection.

Tramutola A, Abate G, Lanzillotta C, Triani F, Barone E, Iavarone F, Vincenzoni F, Castagnola M, Marziano M, Memo M, Garrafa E, Butterfield DA, Perluigi M, Di Domenico F, Uberti D.

Free Radic Biol Med. 2018 Dec;129:430-439. doi: 10.1016/j.freeradbiomed.2018.10.414. Epub 2018 Oct 12.

PMID:
30321702
9.

Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence.

Arena A, Zimmer TS, van Scheppingen J, Korotkov A, Anink JJ, Mühlebner A, Jansen FE, van Hecke W, Spliet WG, van Rijen PC, Vezzani A, Baayen JC, Idema S, Iyer AM, Perluigi M, Mills JD, van Vliet EA, Aronica E.

Brain Pathol. 2019 May;29(3):351-365. doi: 10.1111/bpa.12661. Epub 2018 Nov 20.

PMID:
30303592
10.

Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease.

Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, Gaetani S, Grassi C, Butterfield DA, Cassano T, Perluigi M.

Mol Neurobiol. 2019 Apr;56(4):2922-2943. doi: 10.1007/s12035-018-1231-5. Epub 2018 Aug 2.

PMID:
30073505
11.

Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.

Tramutola A, Sharma N, Barone E, Lanzillotta C, Castellani A, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA, Gaetani S, Cassano T, Perluigi M, Di Domenico F.

Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3309-3321. doi: 10.1016/j.bbadis.2018.07.017. Epub 2018 Jul 18.

12.

Poly-ubiquitin profile in Alzheimer disease brain.

Tramutola A, Triani F, Di Domenico F, Barone E, Cai J, Klein JB, Perluigi M, Butterfield DA.

Neurobiol Dis. 2018 Oct;118:129-141. doi: 10.1016/j.nbd.2018.07.006. Epub 2018 Jul 9.

PMID:
30003951
13.

Biliverdin reductase-A impairment links brain insulin resistance with increased Aβ production in an animal model of aging: Implications for Alzheimer disease.

Triani F, Tramutola A, Di Domenico F, Sharma N, Butterfield DA, Head E, Perluigi M, Barone E.

Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3181-3194. doi: 10.1016/j.bbadis.2018.07.005. Epub 2018 Jul 5.

14.

Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models.

Lanzillotta C, Tramutola A, Meier S, Schmitt F, Barone E, Perluigi M, Di Domenico F, Abisambra JF.

J Alzheimers Dis. 2018;62(1):347-359. doi: 10.3233/JAD-170617.

15.

Down syndrome: From development to adult life to Alzheimer disease.

Butterfield DA, Perluigi M.

Free Radic Biol Med. 2018 Jan;114:1-2. doi: 10.1016/j.freeradbiomed.2017.10.374. Epub 2017 Oct 24. No abstract available.

PMID:
29079527
16.

mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Di Domenico F, Tramutola A, Foppoli C, Head E, Perluigi M, Butterfield DA.

Free Radic Biol Med. 2018 Jan;114:94-101. doi: 10.1016/j.freeradbiomed.2017.08.009. Epub 2017 Aug 12. Review.

17.

Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.

Arena A, Iyer AM, Milenkovic I, Kovacs GG, Ferrer I, Perluigi M, Aronica E.

Curr Alzheimer Res. 2017;14(12):1305-1317. doi: 10.2174/1567205014666170706112701.

PMID:
28720071
18.

Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Barone E, Arena A, Head E, Butterfield DA, Perluigi M.

Free Radic Biol Med. 2018 Jan;114:84-93. doi: 10.1016/j.freeradbiomed.2017.07.009. Epub 2017 Jul 10. Review.

19.

CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis.

Spadaccio C, Nappi F, Al-Attar N, Coccia R, Perluigi M, Di Domenico F.

Drug Target Insights. 2017 Jan 3;10(Suppl 1):15-19. doi: 10.4137/DTI.S41240. eCollection 2016. No abstract available.

20.

HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Barone E, Head E, Butterfield DA, Perluigi M.

Free Radic Biol Med. 2017 Oct;111:262-269. doi: 10.1016/j.freeradbiomed.2016.10.508. Epub 2016 Nov 10. Review.

Supplemental Content

Loading ...
Support Center